CA-C3.AI
C3.ai , a leading enterprise artificial intelligence (AI) software provider for accelerating digital transformation, today announced the winners of the C3.ai™ COVID-19 Grand Challenge . Launched on Sept. 15, the global competition encouraged developers, data scientists, students, and creative minds to build world-class data science techniques and strategies that accelerate novel COVID-19 research and drive smart and safe decision-making. The C3.ai COVID-19 Grand Challenge represents an opportunity to inform decision makers at the local, state, and federal levels and transform the way the world confronts this pandemic.
After a rigorous review process, the judging panel selected seven research projects for recognition. Judges assessed how well the entries leveraged data science techniques to derive insights that were not apparent before. The judges selected submissions that were most likely to unlock significant public health and economic benefits.
A total of $200,000 in cash prizes will be awarded to these research teams. Each has developed meaningful data-driven insights that will help the global community understand and mitigate not only the spread of COVID-19, but also prepare the world to fight future pandemics, improve the medical community’s ability to respond, and help policymakers navigate decisions about COVID-19.
C3.ai Grand Challenge Award Winners:
Grand Prize - $100,000
- Combined Diagnostics - Modeling Population Heterogeneity and Personalized COVID Diagnostics. Predicts an individual’s infectious and susceptibility status and probability of having COVID-19. The team applied the Bayesian Stochastic Expectation-Maximization method to demographics, individual health characteristics, and behavioral and geographical data to provide personalized estimates for each individual’s infectious and susceptibility statuses. (Freddy Bunbury - Carnegie Institution for Science, Nina Miolane - University of California, Santa Barbara, and Claire Donnat - University of Chicago)
“Any return to normality relies on accurately determining who might have COVID-19. Demographics, individual health characteristics, and behavioral and geographical data considerably alter one’s risk of catching, suffering from, and spreading the virus,” said Freddy Bunbury, post-doctoral researcher at the Carnegie Institution for Science. “Knowing this, we developed a machine learning model that is reactive, granular, and even personalized to help individuals, and – by extension – society, compute with greater accuracy the probability of having COVID-19. By intelligently combining these disparate data sources, we aim to more robustly capture people’s individual likelihood of having and spreading the disease, reduce false test results, and inform disease transmission models.”
“This project has huge potential to make an immediate impact on the pandemic with its approach to generating meaningful results from COVID testing,” said Thomas M. Siebel, CEO of C3.ai. “This is an unprecedented opportunity to apply informed decision-making based on data to enable daily life and business operations to continue, while effectively managing health risks.”
Second-Place Awards - $25,000 each
- DeepOutbreak: Framework for Forecasting Dynamics of COVID-19 and Co-Evolving Diseases . Models the progression of COVID-19 and symptomatically similar co-evolving influenza-like illnesses, as well as hospitalization and mortality rates. Designed to optimize healthcare deployment, which is especially important with hospitalizations resurging and healthcare workers increasingly becoming ill. (Alexander Rodriguez, Nikhil Muralidhar, Bijaya Adhikari, Naren Ramakrishnan, and B. Aditya Prakash - U.S.)
- Assessing Conservation Level of Therapeutic and Vaccine Targets of COVID-19. Predicts the effectiveness of vaccines and therapeutics by genome sequences and prioritizes relevant treatments to inform drug and vaccine development. (Yuanfang Guan and Manqi Zhou - U.S.)
Third-Place Awards - $12,500 each
- Analysis of COVID-19 Policies’ Impact on the Population and the Economy . Calculates the impact of government policies on COVID-19 infection rates, stock prices, and a population’s mobility to inform governments about how policies affect people and the economy. (Niti Wattanasirichaigoon, Napat Ratanakul, and Apiwat Jaroonpol - U.S., Singapore, and Japan)
- COVIDProf: An Intelligent Q&A Chatbot Tuned to Deliver Scientific Research and Data Related to COVID-19 in Natural Language. Makes finding and understanding relevant COVID-19 scientific research and data easier for the average person through an intelligent Q&A chatbot. (Varsha Rao and Joy Yeh - Singapore and Japan)
- Structural Modeling of COVID Spread in Relation to Human Mobility . Models causal relationships between human mobility indicators (trips, distance traveled, staying at home, and social distancing) and COVID-19 spread to inform how policymakers should take action. (Rezwana Rafiq, Tanjeeb Ahmed, and Md Yusuf Sarwar Uddin - U.S.)
- The Center on Stochastic Modeling, Optimization, and Statistics (COSMOS) COVID -19 Linear Programming. Online tool for reopening communities that enables decision makers to study hypothetical scenarios to inform planning and protect high-risk individuals. (Victoria Chen, Yuan Zhou, Nilabh Ohol, Alireza Fallahi, and Amith Viswanatha - U.S.)
Award Criteria
The projects were reviewed on the basis of their scientific merit, the use of AI, machine learning, and/or other data science techniques in the project, and the incorporation of at least two data sources from the C3 AI® COVID-19 Data Lake .
The evaluation process also considered the extent to which the derived data science insights, if implemented at scale, will result in significant public health and economic benefit.
To learn more about the C3.ai COVID-19 Grand Challenge, please visit https://c3.ai/c3-ai-covid-19-grand-challenge/ .
About C3.ai
C3.ai is a leading AI software provider for accelerating digital transformation. C3.ai delivers the C3 AI Suite for developing, deploying, and operating large-scale AI, predictive analytics, and IoT applications in addition to an increasingly broad portfolio of turnkey AI applications. The core of the C3.ai offering is a proprietary, model-driven AI architecture that dramatically enhances data science and application development.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201208005727/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom